Oncogenic human papillomaviruses (HPVs) attach predominantly to extracellular matrix (ECM) components during infection of cultured keratinocytes and in the rodent vaginal challenge model in vivo. However, the mechanism of virion transfer from the ECM to receptors that mediate entry into host cells has not been determined. In this work we strove to assess the role of heparan sulfate (HS) chains in HPV16 binding to the ECM and determine how HPV16 release from the ECM is regulated. We also assessed the extent to which capsids released from the ECM are infectious. We show that a large fraction of HPV16 particles binds to the ECM via HS chains, and that syndecan-1 (snd-1) molecules present in the ECM are involved in virus binding. Inhibiting the normal processing of snd-1 and HS molecules via matrix metalloproteinases and heparanase dramatically reduces virus release from the ECM, cellular uptake and infection. Conversely, exogenous heparinase activates each of these processes. We confirm that HPV16 released from the ECM is infectious in keratinocytes. Use of a specific inhibitor shows furin is not involved in HPV16 release from ECM attachment factors and corroborates other studies showing only the intracellular activity of furin is responsible for modulating HPV infectivity. These data suggest that our recently proposed model, describing the action of HS proteoglycan processing enzymes in releasing HPV16 from the cell surface in complex with the attachment factor snd-1, is also relevant to the release of HPV16 particles from the ECM to promote efficient infection of keratinocytes.
INTRODUCTION
Human papillomaviruses (HPVs) are small DNA-containing viruses that initiate benign and malignant epithelial tumours. HPV16 is the prototype of the oncogenic HPVs, causing genital and oral infections, and is a major cause of premalignant lesions and cancers in the same mucosal tissues (Chesson et al., 2012; Forman et al., 2012) . The entry of HPV particles into human keratinocyte (HK) host cells is a multistep process initiated by binding to primary attachment factors, most commonly the heparan sulfate (HS) chains of proteoglycans (HSPGs) (Joyce et al., 1999; Combita et al., 2001; Giroglou et al., 2001) . The interaction of HPV16 major capsid protein (L1) with the HS chain of proteoglycans is well characterized, but generally considered to play a passive role in infection (Knappe et al., 2007; Dasgupta et al., 2011) .
Syndecan-1 (snd-1), the most abundant HSPG in keratinocytes, serves as an HPV attachment receptor (Selinka et al., 2002; Shafti-Keramat et al., 2003) . Snd-1 is expressed primarily on epithelial cell basolateral surfaces (Rapraeger et al., 1986; Hayashi et al., 1987; Kim et al., 1994) , and binds tightly to the extracellular matrix (ECM) components collagen (Koda et al., 1985) , the fibronectins (Saunders & Bernfield, 1988) and laminin-332 (LN-332, formerly LN-5) (Okamoto et al., 2003; Rousselle & Beck, 2013) . The HS chains of snd-1 proteoglycans accumulate various active ligands, including ECM proteins, proteinases, growth factors (GFs), cytokines, chemokines, and present these ligands to high-affinity cell-surface receptors (Yoneda & Couchman 2003; Choi et al., 2011) . The ectodomains of all HS-chain-enriched snd-1 molecules are constitutively released (i.e. shed) from cell membranes as part of normal physiology (Bishop et al., 2007) . Shed ectodomains bound to bioactive ligands (e.g. GFs) in soluble form also deliver ligands to their high-affinity, cognate receptors (Elenius & Jalkanen, 1994; Bernfield et al., 1999; Okamoto et al., 2003; Fears & Woods, 2006; Choi et al., 2010 Choi et al., , 2011 , or they can attach to and accumulate within the ECM (Bayer-Garner et al., 2001; Ding et al., 2005) . Proteases, including matrix metalloproteinases (MMPs) and ADAM sheddases, mediate the ectodomain shedding of membrane-bound proteins (such as snd-1) (Flannery, 2006; Lambaerts et al., 2009; Choi et al., 2010; Pruessmeyer et al., 2010) ; HS moieties on snd-1 are processed by heparanase, which cleaves HS to release fragments that are 10-20 sugar residues long. Processed HS molecules are more bioactive than their native HS chains, and act as potent promoters of GF activity (Kato et al., 1998; Elkin et al., 2001 ).
Previously, we showed snd-1 shedding plays an active role in HPV16 infection in cultured HKs (Surviladze et al., 2012) . Instead of dissociating from HS chains, HPV particles are released from the cell surface during normal HSPG processing. HPV particles remain complexed with HS and GFs, particularly ligands specific to epidermal GF receptor (EGFR). We reported that inhibiting MMP activity and subsequent HSPG shedding significantly decreases virus release and infection. The specificity of the GFs appears to bridge the virus to interact with cognate cellular receptors (i.e. a receptor tyrosine kinase/GFR), where subsequent signalling promotes infection. The importance of EGFR signalling in HPV infectious entry into HKs was subsequently confirmed (Schelhaas et al., 2012) .
Considering HSPG biology, it is logical that HSPG-bound HPV particles would associate with the ECM. Membranebound and shed syndecan forms attach tightly to the ECM via their HS chains. Additionally, the ECM functions as a scaffold for secreted polysaccharides (Bishop et al., 2007) . Indeed, many studies demonstrated that HPV particles accumulate on the ECM, and LN-332, an ECM-resident, is a proposed HPV attachment factor (Culp et al., 2006a, b; Smith et al., 2008) . Recent work suggests direct protein-protein interaction between HPV16 and LN-332 (Cerqueira et al., 2013) . HS was found to be important for HPV16 and HPV18 binding to the ECM , but was unnecessary for HPV11 (Culp et al., 2006a) . Although these studies used various cell lines and HPV types, ECM-attached virus was deemed infectious. Our previous work showed HPV virions bound to keratinocyte ECM are immobile, but that bound virus disappeared over time coincident with particle uptake by filopodia (Smith et al., 2008) . Nevertheless, whether HS chains play a specific role in HPV binding to the ECM has been unclear, and the mechanism of HPV release from the ECM and transfer to the entry receptors on the keratinocyte surface has remained elusive.
Herein we investigated the mechanics of HPV16 binding to and release from the ECM to facilitate infection of HKs. We used non-carcinogenic HPV16 pseudovirions (PsVs), which are structurally indistinguishable, and deliver a reporter plasmid (pseudogenome) to the cell nucleus as a surrogate marker of infection. Our findings indicate that ECM-attached HPV16 particles are released via the activity of proteases and heparanase, in a manner similar to that which we described for cell-attached virus (Surviladze et al., 2012) .
RESULTS

Furin inhibitor does not alter HPV16 binding to or release from the ECM
The protein convertase furin is proposed to play a role in HPV release from primary attachment factors, especially on the ECM or basement membrane (Kines et al., 2009; Schiller et al., 2010) . If furin is important for the transfer of ECM-bound HPV particles to HKs, then furin inhibition should decrease not only release of bound HPV particles from the ECM but also HPV internalization into cells and total infectivity. To investigate how furin activity influences HPV16-ECM interactions, we used furin inhibitor 1 (also called dec.-RVKR-CMK), initially testing the effect on HPV16 binding to cell-free ECM (isolated as described in Methods and Fig. S1 , available in the online Supplementary Material). HPV16 PsVs were bound to cell-free ECM in the presence or absence of the furin inhibitor. After washing away unbound virus, analysis revealed that furin inhibitor 1 did not significantly alter HPV16 binding to the ECM (P50.989; Figs 1a and S1a); however, the furin inhibitor reduced furin activity in the cell media w60 % (data not shown). Next, we examined in two ways whether furin activity impacted HPV16 PsV release from the ECM. First, we utilized recombinant His-furin (Prepro Tech), which we verified was active and prone to deactivation by furin inhibitor 1 (Fig. S2) . When His-furin was incubated with ECM-bound HPV16, there was no difference in the amount of HPV16 released from the ECM in two independent experiments (Figs 1b and S1b). Second, ECM-bound HPV16 was incubated with complete medium (CM) [Dulbecco's minimal essential medium (DMEM)+10 % FCS] in the presence or absence of the furin inhibitor for 4 h. HPV16 released into the conditioned medium was quantified revealing no significant difference in HPV liberation from the ECM (P50.7682; Figs 1c and S1c). These data demonstrate that furin activity has no effect on the release of HPV16 bound to ECM in vitro.
Furin activity is not required for HPV16 internalization into HKs
To examine furin's role during HPV internalization versus later steps of HK infection, HaCaT cells were seeded atop ECM-bound PsVs in the absence or presence of the furin inhibitor. After 4 h (37 uC), virus uptake by the cells was stopped by transfer to ice. Extracellular HPV16 was removed with a widely used trypsin/EDTA treatment (Pauza & Price, 1988; Campos et al., 2012; Burkard et al., 2014; Ren et al., 2014) combined with a mild acid and high ionic strength wash (Sorkin & Duex, 2010) (Fig. S3) . We found the furin inhibitor had no influence on the levels of HPV16 internalized by HKs grown on ECMbound PsVs (P50.954; Figs 1d and S1d), a result consistent with a report that furin inhibitor 1 did not prevent BPV1 or HPV16 PsV cellular entry (Richards et al., 2006) . Richards et al. (2006) previously showed furin inhibitor 1 blocks HPV16 pseudoinfection. To validate this finding in our hands, we pre-bound HPV16 PsVs to the ECM in the presence of furin inhibitor and then seeded HaCaT cells atop the ECM-bound PsVs as above. The furin inhibitor reduced infection by 99.4 % compared with infection without the inhibitor (Figs 1e and S1e). In this experiment as well as prior work (Richards et al., 2006) , the cell permeability of furin inhibitor 1 makes it difficult to specifically identify the stage(s) of HPV infection at which furin is needed. To focus the inhibitor at infection steps post entry, HaCaT cells were pre-incubated with cell-permeable furin inhibitor 1 for 1 h. Separately, HPV16 PsVs were attached to ECM without furin inhibitor. After thoroughly washing away extracellular furin inhibitor, HaCaT cells were seeded atop the ECM-bound PsVs. Infection was still inhibited *70 % ( Fig. 1e) , with no statistical difference between the two furin-treatment conditions (P50.128), providing further evidence that furin's intracellular action is important for HPV16 infectivity of keratinocytes.
Intracellular furin activity regulates HPV16 infection
Confocal microscopy studies indicated that furin inhibitor 1 blocked HPV infection after capsids arrived in the endosomal compartment (Richards et al., 2006) . We investigated this biochemically by isolating cell fractions enriched in endosomes/lysosomes (EL fraction) and the marker CD63 (Fig. 1f) . PsV-exposed HaCaT cells grown in the presence of the furin inhibitor for 16 h revealed substantial increases in both L1 and L2 capsid proteins in the EL fraction compared with cells without inhibitor (Fig. 1f) . We verified that the furin inhibitor reduced furin activity in the EL fractions after 3 h (Fig. 1g) . The lower level of furin inhibition by this assay (30 %) compared with w95 % infection inhibition most likely reflects differences in incubation times, substrates and/or the presence of other proteases in the EL fractions. Although we find that furin activity does not regulate HPV16 release from the ECM or virus internalization, our data support the published microscopy data indicating that furin is needed for endosomal escape of viral components. We concur that furin's intracellular action is important for HPV16 infection of HKs.
Heparanase and MMPs affect HPV16 infectious transfer from the ECM to keratinocytes
We previously demonstrated that HSPG processing enzymes, the MMPs, are actively involved in HPV16 release from primary attachment factors and HK infection (Surviladze et al., 2012) . Heparanase, an endoglycosidase that cleaves HS side chains and liberates the HSPG-bound GFs, is also active in regulation of HSPG shedding (Purushothaman et al., 2008; Ramani et al., 2013) . We hypothesized that heparanase is involved in HPV release from primary attachment factors and, thus, regulates HPV infectivity. We performed experiments similar to those detailed for the furin inhibitor ( Fig. 1 ) using an MMP inhibitor (batimastat) and release in the presence of furin. ECM-bound virus was incubated with 1.5 ml complete medium (CM), with or without 3 nM His-furin at 37 8C for 3 h. Virus released into the medium was recovered by pull-down then analysed as in (a). (c) HPV16 PsV release from ECM. ECM-bound virus was incubated with 1.5 ml CM at 37 8C for 4 h with and without furin inhibitor. Virus released into the medium was recovered and analysed as in (a, b). (d) HPV16 entry assay. HaCaT cells were seeded atop ECM-bound HPV16 and incubated for 4 h at 37 8C in the presence or absence of furin inhibitor. Extracellular virus was removed as detailed in Methods, and intracellular HPV levels analysed by immunoblot. Graphed is the mean of four independent experiments. (e) Infectious entry of HPV16. HPV16 PsVs were bound to ECM; infectious transfer of virus to HaCaT cells in the absence or presence of furin inhibitor was measured at 24 h post-infection. HaCaT cells were preincubated at 37 8C for 1 h with furin inhibitor. Extracellular furin inhibitor was removed by intensive washing and cells were added to the ECM-bound HPV16. Relative infectivity was scored 24 h post-infection. (f, g) Furin activity in EL fractions. HPV16-exposed HaCaT cells were incubated for 16 h with or without 3 mM furin inhibitor 1. An equal amount of purified EL fraction lysate was fractionated by SDS-PAGE and analysed for capsid proteins using rabbit polyclonal HPV16 antibody. CD63 (an EL fraction-specific protein detected with anti-CD63 mAb) was detected as a loading control (f). (g) Furin activity in EL fractions of HKs growing in the presence or absence of 3 mM furin inhibitor 1 for 3 h.
a heparanase inhibitor (OGT211; Tocris Bioscience). Whereas these agents had no measurable effect on HPV16 PsV binding to the ECM, they both reduced virus release from the ECM (Fig. 2a, b) . We also found that MMPs and heparanases are important in HPV16 infectious transfer from the ECM (Fig. 2c) . After binding PsVs to cell-free ECM, HaCaT cells were seeded atop the two. Infectivity assays showed both batimastat and OGT2115 significantly reduced the ability of ECM-bound HPV16 to infect cells.
HPV16 particles attach to the ECM via HS chains
As Fig. 3a) . We confirmed that cross-linking protects ECMresident proteins from proteolytic processing by incubating native and xECM with complete medium for 20 h. After After 1 h at room temperature, unbound PsVs were removed by intensive washing, and ECM-bound virus was solubilized and analysed as described in Fig. 1(a) . (b) HPV-bound ECM was incubated at 37 8C for 3 h with complete medium (CM), or with CM supplemented with 1 mM batimastat or 20 mM OGT2115. Conditioned media were analysed for released HPV16 as described in Fig. 1(b) . ( washing to remove unbound proteins, we found DTSSP cross-linking inhibited LN-332 degradation by *2-fold (Fig. 3b) . At the same time, HPV16 release from the xECM decreased *50 % compared with the amount of virus released from native ECM (Fig. 3c ). This suggests that some PsVs bind to ECM-resident proteins, or that binding avidity increased in large cross-linked structures. Nevertheless, heparinase III treatment doubled the release of PsVs bound to xECM (Fig. 3d) , indicating a sizeable proportion of HPV16 particles bind the ECM via HS chains.
ECM-resident snd-1 is involved in HPV16 binding to the ECM
Shed snd-1 molecules accumulate in the ECM (BayerGarner et al., 2001; Ding et al., 2005) and are also primary cell-surface receptors for HPV16 (Selinka et al., 2002; Shafti-Keramat et al., 2003) . Thus, we hypothesized that ECM-resident, shed snd-1 molecules (containing HS chains) are involved in ECM binding by HPV16. We first confirmed the presence of snd-1 proteoglycans in native and xECM (Fig. 4a) . We then used immunoprecipitation (IP) for snd-1 (Fig. S4 ) to show that L1 interacts with ECM-associated snd-1 (Fig. 4b) . The stringent IP conditions suggest high-affinity interactions similar to those between L1 and HSPG (Joyce et al., 1999) . HPV16 attachment to ECM, however, does not affect snd-1 binding to LN-332 (Fig. 4c) .
Cleavage of HS chains increases HPV16 release from the ECM concomitant with increased HK entry and infection
A role for HS chain-processing enzymes in HPV infection has not been investigated. We predicted ECM-resident HS chains should be free from DTSSP protein cross-linking and remain susceptible to heparinase. We then determined that heparinase III increases HPV16 release from xECM to promote infection (Fig. 5) . In a variation of experiments shown in Fig. 3(c, d ), HKs were seeded atop native or xECM-bound virus. Consistent with results in Fig. 3(c) , xECM reduced the release of bound HPV16 PsVs by *65 % compared with virus release from native ECM (Fig. 5a ). However, heparinase III restored HPV16 release from xECM (Fig. 5a ), similar to data in Fig. 3(d (Fig. 5b, c) . Similar to increased HPV16 release from xECM in the presence of heparinase III, the presence of heparinase III doubled the amount of internalized virus as well as infection levels (P50.02) in cells compared with samples without heparinase (Fig. 5b, c) . In summary, ECM-protein cross-linking did not affect HPV16 binding, but decreased HPV release from the ECM, cellular internalization and infection levels in HaCaT cells. Promoting HS chain processing in protein xECM proportionately restored HPV16 released from the ECM, HK entry and infection. These findings provide strong evidence that HPV particles interact with HS chains in the ECM, and that infection is strongly affected by HS chain processing in the ECM.
HPV16 PsV released from ECM is infectious
Our data show a strong positive correlation among HPV16 PsV release from the ECM, cellular internalization of virus particles, and infection when HaCaT cells were seeded atop ECM-containing virus. We verified infection is directly proportionate to the amount of HPV16 released from the ECM by collecting released virus and testing dose-dependent infection. Analysis revealed a linear dose-response relationship between the concentration of HPV16 PsV released from the ECM and HK infectivity (Fig. 6 ).
DISCUSSION
HPVs have long been known to interact with cell-surface HSPGs (Joyce et al., 1999; Combita et al., 2001; Giroglou et al., 2001) , and to bind strongly to ECM secreted by keratinocytes and other epithelial cells (Culp et al., 2006a, b; Day et al., 2007) . Yet, ECM moieties responsible for HPV interaction and the mode of virus transfer from these molecules to plasma membrane receptors responsible for virus PsVs were bound to native ECM for 1 h; unbound virus was removed by intensive washing and extracted with RIPA buffer. IP was performed using anti-snd-1 rabbit polyclonal antibody coupled to Protein A-magnetic beads.
Immunoblot was performed for snd-1 (see Fig. S4 ), HPV16 L1 (b) and . Three independent experiments verified that PsVs associate with snd-1 in the ECM.
entry into host keratinocytes have not been clearly defined. Herein we demonstrate that HS chain-processing enzymes augment the release and infectivity of ECM-bound HPV PsVs, indicating that considerable numbers of virus particles attach to the ECM via these HS chains. We found shed, ECM-resident snd-1 interacts with HPV16 and with LN-332, demonstrating snd-1 is an ECM attachment factor for HPV16, in addition to its role binding HPVs on the plasma membrane (Shafti-Keramat et al., 2003; Surviladze et al., 2012) . The interaction of snd-1 with LN-332 is expected on the basis of reports that shed snd-1 molecules with their native HS chains are concentrated in the ECM (Bayer-Garner et al., 2001; Ding et al., 2005) , and that LN-332 binds plasma membrane resident snd-1 with high affinity and specificity via HS chains (Rapraeger et al., 1986; Bernfield et al., 1999; Okamoto et al., 2003) . LN-332 has been identified as an ECM-resident HPV attachment factor (Culp et al., 2006a,b; Selinka et al., 2007; Cerqueira et al., 2013) . As LN-332 intrinsically lacks HS chains, but contains HS-binding domains (Sung et al., 1997; Carulli et al., 2012) , it seems more likely that HS chains bridge the HPV-LN-332 interaction, and this could account for ECM co-localization between HPV and LN-332 (Culp et al., 2006; Cerqueira et al., 2013) . Indeed, our findings indicate that the normally processed HS chains of snd-1, and perhaps other HSPGs, comprise ECM-resident HPV receptors. However, we cannot rule out the existence of other non-HSPG receptors in the ECM, including LN-332. Highly charged HPV particles may associate with many other molecules.
We found no evidence that furin plays a role in extracellular HPV-keratinocyte interactions or transfer of ECMattached virions to receptors responsible for virus entry. Our results are consistent with previous reports, showing furin's activity is dispensable for HPV endocytic entry, and that furin inhibitor 1 caused HPV accumulation in late endosomal compartments (Richards et al., 2006; Day & Schelhaas, 2014) . Extracellular furin is suggested to catalyse HPV capsid conformational changes by cleaving L2, which then promotes dissociation from HSPGs and interaction with a non-HSPG cell-surface receptor that promotes entry (Day et al., 2008) . However, our data showing equivalent entry in the presence or absence of furin inhibitor fail to support this idea.
This work reveals two aspects about ECM binding by HPV. First, ECM-protein cross-linking had no measurable HPV16 interacts with heparin sulfate and syndecan-1 outcome on HPV16 binding. This means that either HPV attachment to ECM proteins fails to require conformational changes or that HPVs largely bind non-proteinaceous molecules (HS chains of ECM-integrated proteins), which were not DTSSP cross-linked. Second, it seems unlikely that HPV capsid conformational changes are required for release from ECM-factors and subsequent infectious host cell entry. This is based on finding similar binding efficiencies of HPV16 to native and xECM, strongly indicating that the same attachment molecules are engaged by virus on the two matrices. Similar virus-ECM binding should result in equivalent capsid conformational changes, which, if essential for virus release and infectivity, should cause equal HPV release from primary attachment factors, and similar infectivity of the cells grown over native or xECM. Yet, comparing activities following binding to native or xECM, virus release from xECM, HK entry and cell infectivity was reduced by *50-70 %. We cannot exclude the possibility that conformational changes in HPV L1 and L2 proteins occur during interaction with plasma membrane components. However, to our knowledge there is no direct evidence that capsid conformational changes are necessary for the release of HPV16 from an attachment factor, particularly HSPGs.
Models have been proposed to explain the mechanism of HPV release from HSPGs and particle movement to receptor(s) responsible for virus entry. One suggests that conformational changes in the virus capsid structure are brought about by HSPG binding, which then allows furin cleavage of HPV L2 protein, and subsequently triggers HPV release from attachment factors that passively accumulate virus particles on their HS chains (Schiller et al., 2010) . We proposed a model based upon the physiological processing of HSPG molecules, wherein HPV particles are released from the cell surface still in complex with HS and GFs, and signal via GFRs to promote infection (Surviladze et al., 2012) . Neither of these models addressed the release and infectivity of ECM-bound virus, but our findings herein suggest the applicability of our model where HPVs highjack normal HSPG processing to gain infectious entry into keratinocytes (Fig. 7) . The inhibited viral release from the ECM, cellular entry and infectivity from xECM can be readily explained by our model where proteases and heparanase play an important role in HPV release from primary receptors.
Our model wherein HPVs usurp HSPG processing and GFR/RTK signalling to promote infection resonates with a role for epithelial wounding in mediating papillomavirus infections in vivo (Shope & Hurst, 1933) . Epithelial breaks result in an influx of GFs and cytokines involved in regulating syndecan shedding (Choi et al., 2011) . Snd-1 expression is strongly upregulated in migrating and proliferating keratinocytes, and shed syndecans present in wound fluids regulate GFs (Kato et al., 1998) and MMP activities (Tokumaru et al., 2000) . Thus, HPVs appear to have evolved to commandeer the epithelial wound, not only to gain access to mitotically active basal cells, but also to usurp wound-responsive factors and architecture that promote infection. Many intracellular pathogens of the female genital tract (HIV, herpesviruses, Chlamydia, Neisseria), interact with cellular HSPGs (Liu & Thorp, 2002) . It is thus tempting to speculate these pathogens also appropriate HSPG biology during infection. In summary, our work provides new insights into the transmission of oncogenic HPVs and underscores that pathogens highjack normal cell functions during infection of their hosts. These findings may point to additional targets for preventing HPV infections, and potentially those of similarly acting pathogens.
METHODS
Cell culture, pseudovirion production and infections. HaCaT cells were grown as reported previously (Surviladze et al., 2012) . All 37 uC incubations were in 5 % CO 2 . Luciferase-expressing HPV16 PsVs were produced, isolated and quantified as described previously (Campos & Ozbun, 2009; Surviladze et al., 2012) . Infections were initiated using PsVs at 100-200 viral genome equivalents per cell and quantified 24 h post exposure as reported previously (Surviladze et al., 2012) . Raw data were normalized by protein content.
HPV particle internalization assay. Extracellular virus was removed by treatment with 0.25 % trypsin/5 mM EDTA for 15 min, 37 uC. Pelleted cells were washed with ice-cold PBS and treated with ice-cold 0.1 M sodium acetate buffer (pH 4.5) containing 0.5 M NaCl for 2 min, 4 uC. Cells were washed three times with PBS and lysed with RIPA buffer.
Immunoprecipitation (IP), SDS-PAGE and immunoblotting.
ECM lysates were prepared in RIPA buffer [50 mM Tris (pH 7.5), 0.1 % SDS, 1 % sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 1 mM sodium vanadate, 1 mM PMSF, 10 ng leupeptin ml 21 , 10 ng aprotinin ml 21 ]. Supernatants (post 10 min at 17 000 g, 4 uC) were subjected to IP or dissolved in Laemmli sample buffer containing 2 % SDS and 5 % b-mercaptoethanol. Affinity purified polyclonal anti-snd-1 antibody coupled to protein A magnetic beads was used for snd-1 IP. After 1 h of incubation at 4 uC, beads were washed with RIPA buffer and PBS and resuspended in Laemmli sample buffer. Samples were boiled and fractionated by SDS-PAGE, transferred onto Immobilon-P membranes (Millipore), and analysed with various antibodies: anti-HPV16 L1 mouse mAb (CAMVIR-1); anti-LN-332 alpha chain mouse mAb (clone P3E4); anti-actin goat polyclonal antibody; anti-CD63 mouse mAb, antisyndecan-1 mouse mAb and goat polyclonal Ab (all from Santa Cruz Biotech); affinity purified anti-syndecan-1 rabbit polyclonal antibody (Millipore). Antigen-antibody interactions and visualizations were as reported previously (Surviladze et al., 2012) . Stripped blots were reprobed with actin antibody; after scanning, the intensity of individual bands was quantified using AlphaEaseFC (Alpha Innotech).
Preparation of HK ECM. HaCaT cell-derived ECM was prepared as described by Kariya et al. (2012) . Briefly, subconfluent cells were removed from plates by incubation with 10 mM EDTA and washing three times with PBS. Cells remaining on the plates were completely removed with 20 mM NH 4 OH for 5 min, room temperature (RT) and additional PBS washing. ECM preparations were verified microscopically to be cell-free. ECM was incubated with DMEM/FCS or BSA for 1 h, RT to reduce non-specific binding.
Keratinocyte-to-ECM add-back experiments. ECM was prepared as described above. PsVs were added and incubated for 1 h, RT.
IP: 54.70.40.11
On: Sun, 13 Jan 2019 01:41:48 Unbound PsVs were removed by washing three times with PBS and twice with complete medium (CM). HaCaT cells were seeded to be 60 % confluent atop ECM-bound PsVs.
Soluble HPV16 pull-down assay. ECM-bound HPV16 was washed intensively and incubated at 37 uC in CM. Media were collected after various time points, centrifuged to remove cell debris, and released PsVs were captured with heparin-agarose beads (Sigma-Aldrich) for 1 h, 4 uC (Joyce et al., 1999; Kim et al., 2009; Faust et al., 2010) . Beads were washed three times with PBS, resuspended with SDS sample buffer, and analysed by SDS-PAGE and immunoblot for HPV16 L1.
ECM cross-linking. ECM components were cross-linked with 1 mM DTSSP (Thermo Scientific) following the manufacturer's instructions; reactions were quenched with 50 mM Tris pH 7.5 for 15 min, RT. After three PBS washes, 1 % BSA was added for 1 h, RT to reduce non-specific interactions on the plate.
Isolation of EL fraction. HPV16-bound HaCaT cells were cultivated for 24 h in the presence of 3 mM furin inhibitor 1 (dec.-RVKR-CMK; Millipore), then washed with PBS. Fractionation buffer (10 mM Tris, pH 7.0, 250 mM sucrose) was added, cells were dislodged manually, then passed ten times through a 27-gauge needle. The EL fraction was obtained as described by Schröter et al. (1999) , resuspended in furin assay buffer (100 mM HEPES, pH 7.4, 0.5 % Triton X-100, 1 mM CaCl 2 and 1 mM b-mercaptoethanol).
Furin activity. Fluorometric assays were performed as reported by Molloy et al. (1992) . Briefly, the reaction contained 75 mM Boc-RVRR-AMC furin substrate (Enzo Biochem) in assay buffer and 3 nM recombinant furin, conditioned medium or EL lysate for 3 h, 30 uC. In some cases 3 mM furin inhibitor 1 was present. The AMC cleavage peptide was quantified by fluorometry (380 nm excitation, 460 nm emission).
